TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

06 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

05 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

17 7 2024 09:58:20 提供 NetDania Notify

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

07 6 2024 07:50:00 提供 Nasdaq GlobeNewswire

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

03 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

31 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

28 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

01 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

30 4 2024 16:55:29 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

18 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

18 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

15 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

08 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

01 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

28 2 2024 07:00:01 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

27 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

26 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

23 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

20 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

10 1 2024 07:00:00 提供 Nasdaq GlobeNewswire